SCHEMBL8282124

SCHEMBL8282124

NC(Cc1cccc(Cl)c1)C1CCN(C(=O)N2CCCC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.47
DPP4 P27487 6/20 0.44
DPP7 Q9UHL4 4/20 0.44
DPP8 Q6V1X1 3/20 0.44
DPP9 Q86TI2 3/20 0.44
HDAC8 Q9BY41 1/20 0.43
PNMT P11086 1/20 0.43
EPHX2 P34913 1/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 1/20 0.40
AKT1 P31749 1/20 0.40
AKT2 P31751 1/20 0.40
AKT3 Q9Y243 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8282125 0.90 AKR1C3 (0.52) F2HDAC8ALDH1A1
SCHEMBL8279784 0.86 ADRB2 (0.50) F2DPP4DPP7DPP8DPP9
SCHEMBL8279781 0.84 F2 (0.43) F2DPP4DPP7DPP8DPP9
SCHEMBL14355378 0.84 ATM (0.57) DPP4DPP7DPP8DPP9MEN1
SCHEMBL8280943 0.84 CHRM2 (0.54) DPP4HDAC8MEN1ALDH1A1KMT2A
SCHEMBL14355374 0.82 HDAC8 (0.45) F2DPP4DPP7DPP8DPP9
SCHEMBL5571269 0.82 HDAC8 (0.45) F2DPP4DPP7DPP8DPP9
SCHEMBL5188797 0.82 HDAC8 (0.45) F2DPP4DPP7DPP8DPP9
SCHEMBL5187640 0.81 DPP4 (0.60) F2DPP4
SCHEMBL8280987 0.80 PKM (0.46) F2DPP4DPP7DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265261-A1 Dpp-IV Inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-11-15 US disclosed
US-20070265261-A1 Dpp-IV Inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-11-15 US disclosed
WO-2005121089-A1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265261-A1 Dpp-IV Inhibitors DPP4, DPP3, DPP7 F2 1775/4885DPP4 1/4885DPP7 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.